Compare USAS & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | USAS | GHRS |
|---|---|---|
| Founded | 1998 | 2018 |
| Country | Canada | Ireland |
| Employees | N/A | N/A |
| Industry | Metal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 2.0B |
| IPO Year | 2004 | 2021 |
| Metric | USAS | GHRS |
|---|---|---|
| Price | $5.62 | $28.92 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | $6.50 | ★ $41.38 |
| AVG Volume (30 Days) | ★ 4.7M | 322.1K |
| Earning Date | 05-11-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $174.68 | N/A |
| Revenue Next Year | $53.17 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.32 | $11.83 |
| 52 Week High | $10.50 | $31.44 |
| Indicator | USAS | GHRS |
|---|---|---|
| Relative Strength Index (RSI) | 61.54 | 51.79 |
| Support Level | $4.88 | $28.05 |
| Resistance Level | $6.24 | $28.96 |
| Average True Range (ATR) | 0.24 | 1.44 |
| MACD | 0.06 | -0.27 |
| Stochastic Oscillator | 85.25 | 37.19 |
Americas Gold And Silver Corp is a mining company engaged in the acquisition, exploration, development, and production of precious metals mineral properties in Mexico and the United States. The company's primary operating assets, which are also its reporting segments, are the Cosala operations, the Galena Complex, and Relief Canyon. It also holds interests in the San Felipe Development Project located in Sonora, Mexico. The Cosala operations segment, which derives maximum revenue, operates in Mexico, while the Galena Complex and Relief Canyon segments operate in the United States.
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.